Alzheimer's disease (AD) is a progressive neurodegenerative disease and accounts for
most cases of dementia. The prevalence of AD has increased in the current rapidly aging …

In mammalian cells, two cellular organelles, mitochondria and peroxisomes, share the ability
to degrade fatty acid chains. Although each organelle harbors its own fatty acid β-oxidation …

Alzheimer's disease (AD) is a common neurodegenerative disorder in the elderly
characterized by memory loss and cognitive dysfunction. The pathogenesis of AD is …

Aim of the review This study aimed to reveal the classical signal pathways and important
potential targets of traditional Chinese medicine (TCM) for treating Alzheimer's disease (AD) …

Circadian disruptions impact nearly all people with Alzheimer's disease (AD), emphasizing
both their potential role in pathology and the critical need to investigate the therapeutic …

Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors
including PPARα, PPARγ, and PPARβ/δ, acting as transcription factors to regulate the …

Peroxisome proliferator-activated receptor (PPAR) β/δ belongs to the family of hormone and
lipid-activated nuclear receptors, which are involved in metabolism of long-chain fatty acids …

Palmitoylethanolamide (PEA, N-hexadecanoylethanolamide) is an endogenous compound
belonging to the family of N-acylethanolamines. PEA has anti-inflammatory and analgesic …

Saliva is one of the important body fluids that reflects normal internal characteristics and
disease state of an individual. As a multi-composition oral fluid, has high potential for the …

Novel agents addressing non-amyloid, non-tau targets in Alzheimer's Disease (AD)
comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most …